Display options
Cite
Li S, Chen X, Li Q, et al. Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial. J Diabetes Investig. 2016;7(5):777-85doi: 10.1111/jdi.12493.
Li, S., Chen, X., Li, Q., Du, J., Liu, Z., Peng, Y., Xu, M., Li, Q., Lei, M., Wang, C., Zheng, S., Zhang, X., Yu, H., Shi, J., Tao, S., Feng, P., & Tian, H. (2016). Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial. Journal of diabetes investigation, 7(5), 777-85. https://doi.org/10.1111/jdi.12493
Li, Sheyu, et al. "Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial." Journal of diabetes investigation vol. 7,5 (2016): 777-85. doi: https://doi.org/10.1111/jdi.12493
Li S, Chen X, Li Q, Du J, Liu Z, Peng Y, Xu M, Li Q, Lei M, Wang C, Zheng S, Zhang X, Yu H, Shi J, Tao S, Feng P, Tian H. Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial. J Diabetes Investig. 2016 Sep;7(5):777-85. doi: 10.1111/jdi.12493. Epub 2016 Mar 28. PMID: 27180954; PMCID: PMC5009142.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Investig. 2016 Sep;7(5):777-85. doi: 10.1111/jdi.12493. Epub 2016 Mar 28.

Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial.

Journal of diabetes investigation

Sheyu Li, Xiang Chen, Qianrui Li, Juan Du, Zhimin Liu, Yongde Peng, Mian Xu, Qifu Li, Minxiang Lei, Changjiang Wang, Shaoxiong Zheng, Xiaojuan Zhang, Hongling Yu, Jinyu Shi, Shibing Tao, Ping Feng, Haoming Tian

Affiliations

  1. Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.
  2. Laboratory of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.
  3. Department of Endocrinology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
  4. Department of Endocrinology and Metabolism, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai, China.
  5. Department of Endocrine and Metabolic Diseases, The Second Affiliated Hospital of Kunming Medical College, Kunming, China.
  6. Department of Endocrinology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
  7. Department of Endocrinology, Xiangya Hospital of Central South University, Changsha, China.
  8. Department of Endocrinology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  9. Department of Endocrinology and Metabolism, The Second Hospital of Tianjin Medical University, Tianjin, China.
  10. Statistics Department of GCP Center, West China Hospital, Sichuan University, Chengdu, China.

PMID: 27180954 PMCID: PMC5009142 DOI: 10.1111/jdi.12493

Abstract

AIMS/INTRODUCTION: To assess the efficacy and safety of acetyl-L-carnitine (ALC) on diabetic peripheral neuropathy compared with methylcobalamin (MC).

MATERIALS AND METHODS: This was a multicenter, randomized, parallel-group, double-blind, double-dummy, positive-controlled, non-inferior phase II clinical trial. Diabetic patients with abnormal nerve conduction test results were randomized in a 1:1 ratio to receive oral ALC 500 mg t.i.d. or MC 0.5 mg t.i.d. for 24 weeks. The neuropathy symptom score, neuropathy disability score and neurophysiological parameters were measured during follow up.

RESULTS: A total of 232 patients were randomized (ALC n = 117, MC n = 115), 88% of which completed the trial. At week 24, patients from both groups had significant reductions in both neuropathy symptom score and neuropathy disability score with no significant difference between two groups (neuropathy symptom score reduction: ALC vs MC 2.35 ± 2.23, P < 0.0001 vs 2.11 ± 2.48, P < 0.0001, intergroup P = 0.38; neuropathy disability score reduction ALC vs MC 1.66 ± 1.90, P < 0.0001 vs 1.35 ± 1.65, P < 0.0001, intergroup P = 0.23). Neurophysiological parameters were also improved in both groups. No significant difference was found between groups in the development of adverse events.

CONCLUSIONS: ALC is as effective as MC in improving clinical symptoms and neurophysiological parameters for patients with diabetic peripheral neuropathy over a 24-week period with good tolerance.

© 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Keywords: Acetyl-L-carnitine; Diabetic peripheral neuropathy; Methylcobalamin

References

  1. Tumori. 2005 Mar-Apr;91(2):135-8 - PubMed
  2. HIV Clin Trials. 2005 Nov-Dec;6(6):344-50 - PubMed
  3. Neurology. 1998 Sep;51(3):695-702 - PubMed
  4. Biochem Biophys Res Commun. 1973 Dec 10;55(3):736-42 - PubMed
  5. Neurology. 1992 Sep;42(9):1823-5 - PubMed
  6. J Peripher Nerv Syst. 1996;1(2):157-63 - PubMed
  7. Diabetes Metab Res Rev. 2000 Nov-Dec;16(6):408-33 - PubMed
  8. PLoS One. 2015 Mar 09;10(3):e0119479 - PubMed
  9. J Clin Invest. 1996 Apr 15;97(8):1900-7 - PubMed
  10. J Peripher Nerv Syst. 2006 Mar;11(1):72-6 - PubMed
  11. Expert Rev Neurother. 2013 Aug;13(8):925-36 - PubMed
  12. Diabetologia. 1993 Feb;36(2):150-4 - PubMed
  13. Int J Clin Pharmacol Res. 1995;15(1):9-15 - PubMed
  14. Diabetes. 1988 Jul;37(7):1000-4 - PubMed
  15. Diabetes Care. 2004 Jun;27(6):1458-86 - PubMed
  16. J Diabetes Investig. 2016 Sep;7(5):777-85 - PubMed
  17. PM R. 2011 Apr;3(4):345-52, 352.e1-21 - PubMed
  18. J Diabetes Complications. 2010 Sep-Oct;24(5):354-60 - PubMed
  19. HIV Med. 2007 May;8(4):241-50 - PubMed
  20. Drugs R D. 2002;3(4):223-31 - PubMed
  21. Oncologist. 2013;18(11):1190-1 - PubMed
  22. Electromyogr Clin Neurophysiol. 2005 Sep-Oct;45(6):343-51 - PubMed
  23. Diabetes. 1997 Sep;46 Suppl 2:S90-3 - PubMed
  24. PLoS One. 2010 Dec 28;5(12):e14433 - PubMed
  25. Lancet. 1998 Dec 19-26;352(9145):1978-81 - PubMed
  26. Mol Cell Biochem. 1983;57(1):3-15 - PubMed
  27. J Clin Oncol. 2013 Jul 10;31(20):2627-33 - PubMed
  28. Neural Plast. 2013;2013:424651 - PubMed
  29. Endocr Pract. 2011 Mar-Apr;17 Suppl 2:1-53 - PubMed
  30. Metabolism. 1996 Jul;45(7):865-72 - PubMed
  31. Diabetes Care. 2005 Jan;28(1):89-94 - PubMed
  32. Diabet Med. 2004 Feb;21(2):114-21 - PubMed
  33. Diabetes Res Clin Pract. 2013 Aug;101(2):99-105 - PubMed
  34. Diabetologia. 1995 Jan;38(1):123 - PubMed
  35. Diabet Med. 1998 Jul;15(7):539-53 - PubMed
  36. Eur J Cancer. 2005 Aug;41(12):1746-50 - PubMed
  37. Diabetes. 1979 Oct;28(10):878-87 - PubMed
  38. Life Sci. 1990;47(26):2395-400 - PubMed

Substances

MeSH terms

Publication Types